These findings are compatible with observations after the third vaccine dose in the CLARITY-IBD,28 PREVENT-COVID,29 and HERCULES studies,30 but contrast with a recent Canadian study in which anti-TNF therapy was not associated with a significant reduction in anti-SARS-CoV-2 spike antibody titre following three doses of vaccine.11 The gene discussed is TNF; the disease is inflammatory bowel disease.